Calypte Biomedical to Host 3rd Quarter Financial Results Conference Call On November 17 ALAMEDA, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that management will host a conference call Monday, November 17, to discuss the Company's third quarter financial results as well as provide an update on the Company's current activities at 12:00 p.m. Eastern Time. The company intends to file SEC form 10QSB today, November 14, followed by a press release outlining the activities of the third quarter. The call can be accessed in the U.S. by dialing 800-901-5217 and outside of the U.S. by dialing 617-786-2964. The participant passcode is 58765973. The conference call will also be Web cast live at http://www.calypte.com/. An audio replay of the call will be available, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The account code for the playback is 13337320. The webcast will also be available for replay on the company's website. About Calypte Biomedical Corporation: Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at http://www.calypte.com/. Investor Relations Contact: Tim Clemensen 212-843-9337 email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Tim Clemensen, +1-212-843-9337, , for Calypte Biomedical Corporation Web site: http://www.calypte.com/

Copyright